Polymer-Free Amphilimus-Eluting Stents Vs. Biodegradable-Polymer Everolimus Stents for PCI: 2-year Results of the PARTHENOPE Trial
European Heart Journal Open · 14.11.2026
DOI: 10.1093/ehjopen/oeag187 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Heart Journal Open, online erschienen am 14.11.2026. Verfasst von Raffaele Piccolo und 39 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Drug-eluting stents are the standard of care for percutaneous coronary intervention (PCI), yet long-term evidence on polymer-free stents remains limited.
Aims
The aim of this study was to evaluate the clinical outcomes associated with polymer-free amphilimus-eluting stent (PF-AES) compared with biodegradable polymer everolimus-eluting stent (BP-EES) in patients undergoing PCI at 2 years of follow-up.
Methods
We conducted a randomized, investigator-initiated, assessor-blind, noninferiority trial with minimal exclusion criteria at 14 centers. Patients undergoing PCI were randomized to PF-AES vs. BP-EES. The primary endpoint was a device-oriented composite endpoint (DOCE) of cardiovascular death, target-vessel myocardial infarction, or target-lesion revascularization.
Results
We included 2,107 patients with 3,042 coronary lesions. At 2-years, DOCE occurred at similar rates between patients randomized to PF-AES vs. BP-EES (10.1% vs. 10.6%, hazard ratio, HR, 0.96, 95% confidence intervals, CI, 0.73-1.25, P = 0.74). Rates of individual DOCE components were comparable, including cardiovascular death (4.2% vs. 3.9%), target-vessel myocardial infarction (5.2% vs. 5.6%), and clinically driven target-lesion revascularization (2.3% vs. 2.6%). Landmark analysis showed a significant interaction between randomized stent and follow-up period (P-interaction=0.025). While DOCE rates were similar from 0 to 1 year (8.2% vs. 7.2%; HR 1.15, 95%CI 0.84-1.56), PF-AES was associated with a lower risk of DOCE between 1 and 2 years compared with BP-EES (2.1% vs. 3.7%; HR 0.56, 95%CI 0.32-0.96).
Conclusions
In patients undergoing PCI, PF-AES yielded similar outcomes compared to BP-EES at 2-years. The late benefit with PF-AES warrants further investigation.
Zitieren
APA
Piccolo, R., Laino, A., Carrara, G., Calabrò, P., Simonetti, F., Varricchio, A., Attisano, T., Napolitano, G., Simone, C. D., Carpinella, G., Stabile, E., Cirillo, P., Serafino, L. D., Caiazzo, G., Tesorio, T., Boccalatte, M., Tuccillo, B., Avvedimento, M., Leone, A., …, & Esposito, G. (2026). Polymer-Free Amphilimus-Eluting Stents Vs. Biodegradable-Polymer Everolimus Stents for PCI: 2-year Results of the PARTHENOPE Trial. European Heart Journal Open. https://doi.org/10.1093/ehjopen/oeag187
Vancouver
Piccolo R, Laino A, Carrara G, Calabrò P, Simonetti F, Varricchio A, et al. Polymer-Free Amphilimus-Eluting Stents Vs. Biodegradable-Polymer Everolimus Stents for PCI: 2-year Results of the PARTHENOPE Trial. European Heart Journal Open. 2026. doi:10.1093/ehjopen/oeag187
BibTeX
@article{Piccolo2026,
author = {Piccolo, Raffaele and Laino, Angelo and Carrara, Greta and Calabrò, Paolo and Simonetti, Fiorenzo and Varricchio, Attilio and Attisano, Tiziana and Napolitano, Giovanni and Simone, Ciro De and Carpinella, Gerardo and Stabile, Eugenio and Cirillo, Plinio and Serafino, Luigi Di and Caiazzo, Gianluca and Tesorio, Tullio and Boccalatte, Marco and Tuccillo, Bernardino and Avvedimento, Marisa and Leone, Attilio and Galasso, Gennaro and Cesaro, Arturo and Perrotta, Rocco and Niglio, Tullio and Fimiani, Luigi and Spaccarotella, Carmen Anna Maria and Bardi, Luca and Spinelli, Alessandra and Cristiano, Stefano and Vitale, Antonio Pio and Mariani, Andrea and Leonardi, Sergio and Biscaglia, Simone and Costa, Francesco and Cassese, Salvatore and McFadden, Eugene and Heg, Dik and Stefanini, Giulio G and Franzone, Anna and Capodanno, Davide and Esposito, Giovanni},
title = {Polymer-Free Amphilimus-Eluting Stents Vs. Biodegradable-Polymer Everolimus Stents for PCI: 2-year Results of the PARTHENOPE Trial},
journal = {European Heart Journal Open},
year = {2026},
doi = {10.1093/ehjopen/oeag187}
}
EUVIMED